Cancer immunotherapy: moving beyond current vaccines

Nat Med. 2004 Sep;10(9):909-15. doi: 10.1038/nm1100.

Abstract

Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cancer Vaccines / therapeutic use*
  • Child
  • Clinical Trials as Topic
  • Female
  • Humans
  • Immunotherapy / methods*
  • Male
  • Middle Aged
  • Models, Immunological*
  • Neoplasm Metastasis / immunology
  • Neoplasm Metastasis / therapy*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • T-Lymphocytes / immunology
  • Treatment Outcome
  • Vaccines, Subunit / therapeutic use

Substances

  • Cancer Vaccines
  • Vaccines, Subunit